Australia's R&D Tax Incentive Review report released for consultation

28 September 2016

The government is encouraging feedback from Australia’s research and development community, businesses and industry groups and other stakeholders on the R&D Tax Incentive Review findings released today.

Bill Ferris, chairman, Innovation Australia, Dr Alan Finkel, Chief Scientist, and John Fraser, Secretary to the Treasury, were appointed by the Prime Minister in 2015 to review the current scheme as part of the National Innovation and Science Agenda (NISA). Under the NISA, the Medical Technologies and Pharmaceutical sector is identified as one of the key innovative industries of the future.

The R&D Tax Incentive aims to boost the quality and quantity of R&D undertaken by industry to drive productivity and growth. It is a fundamental part of Australia’s R&D system and accounts for around one-third of the Turnbull government’s support for innovation. In 2013–14, around 13,700 entities generated A$19.5 billion ($15 billion) of R&D at an estimated cost to government of around A$3 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK